Thawing and infusion of CAR-T cell products

Some patients with hematologic malignancies may benefit from chimeric antigen receptor-T (CAR-T) cell treatment. Usually, the manufacture of this cells is carried out by centralized and specialized cell therapy laboratories that cryopreserve the CAR-T cells in bags and send it for infusion in the patient treatment center. In this context, the thawing and infusion of the CAR-T cell products are critical steps in this custody chain. This article aims to discuss the most relevant points related with the CAR-T cell thawing and infusion and proposes a kind of standard operational protocol (SOP) for these processes.